Artivion (NYSE:AORT) CAO Amy Horton Sells 1,731 Shares

Artivion, Inc. (NYSE:AORT) CAO Amy Horton sold 1,731 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $37.59, for a total value of $65,068.29. Following the completion of the transaction, the chief accounting officer directly owned 128,327 shares in the company, valued at approximately $4,823,811.93. This trade represents a 1.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Amy Horton also recently made the following trade(s):

• On Tuesday, February 24th, Amy Horton sold 830 shares of Artivion stock. The shares were sold at an average price of $35.69, for a total transaction of $29,622.70.
• On Monday, December 8th, Amy Horton sold 4,572 shares of Artivion stock. The shares were sold at an average price of $44.42, for a total transaction of $203,088.24.

Artivion Stock Up 3.8%

AORT traded up $1.37 during midday trading on Thursday, hitting $37.15. The company had a trading volume of 56,411 shares, compared to its average volume of 390,480. The stock’s 50 day moving average price is $42.27 and its 200 day moving average price is $43.08. Artivion, Inc. has a 52 week low of $21.97 and a 52 week high of $48.25. The company has a market capitalization of $1.78 billion, a price-to-earnings ratio of 185.77 and a beta of 1.59. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49.

Artivion (NYSE:AORT) last issued its earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The company had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. Artivion’s quarterly revenue was up 19.2% on a year-over-year basis. On average, research analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Artivion

Several large investors have recently made changes to their positions in the business. Verition Fund Management LLC grew its position in Artivion by 1.6% during the third quarter. Verition Fund Management LLC now owns 16,912 shares of the company’s stock valued at $716,000 after buying an additional 274 shares during the period. Entropy Technologies LP increased its stake in shares of Artivion by 6.0% during the 4th quarter. Entropy Technologies LP now owns 5,504 shares of the company’s stock worth $251,000 after purchasing an additional 310 shares during the last quarter. State of Alaska Department of Revenue raised its holdings in shares of Artivion by 1.8% in the 3rd quarter. State of Alaska Department of Revenue now owns 23,294 shares of the company’s stock worth $985,000 after purchasing an additional 414 shares during the period. PNC Financial Services Group Inc. grew its holdings in Artivion by 6.2% during the third quarter. PNC Financial Services Group Inc. now owns 8,232 shares of the company’s stock valued at $349,000 after purchasing an additional 477 shares during the period. Finally, Arizona State Retirement System raised its stake in shares of Artivion by 4.6% in the fourth quarter. Arizona State Retirement System now owns 11,235 shares of the company’s stock valued at $512,000 after buying an additional 494 shares during the period. 86.37% of the stock is owned by hedge funds and other institutional investors.

More Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Company beat recent quarterly estimates — revenue grew ~19% year‑over‑year and EPS topped consensus in the Feb. 12 report, supporting the bullish case for revenue momentum and margin recovery. Earnings & Company Page
• Positive Sentiment: Short interest fell materially in February (down ~15.4% month‑over‑month to ~1.39M shares, ~3.2% of float), lowering near‑term downside pressure from short covering and making upward moves easier to sustain. Short Interest/Insider Page
• Positive Sentiment: Large institutional moves show conviction: several funds (Summit Partners, Invesco, Goldman, Two Sigma) increased or initiated sizeable positions in recent quarters, suggesting longer‑term buy interest from professional investors. Institutional Holdings
• Neutral Sentiment: Analyst coverage is mixed but skewed positive: consensus is a “Moderate Buy” with a ~$49 average target, though several shops have trimmed price targets or moved to hold — signaling diverging views on near‑term upside. Analyst Notes
• Negative Sentiment: Substantial insider selling across senior management over Feb. 23–24 (CEO James P. Mackin sold multiple blocks totaling tens of thousands of shares, plus sales by the EVP, SVPs and CAO). While filings indicate open‑market sales (liquidity/rebalancing), the size and breadth of the dispositions can create short‑term selling pressure and investor unease. SEC filings: CEO Form 4 and related officer filings. CEO Form 4 EVP Form 4

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Citizens Jmp upped their price objective on shares of Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Wall Street Zen lowered shares of Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Weiss Ratings upgraded Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Canaccord Genuity Group dropped their target price on Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $58.00 price target on shares of Artivion in a report on Monday, February 2nd. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.97.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.